![2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]](data:image/svg+xml;base64,PHN2ZyB2aWV3Qm94PSIwIDAgMSAxIiB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==)
Pfizer’s Talzenna combo significantly delays progression in frontline prostate cancer Topline results from the Phase 3 TALAPRO-3 study indicate that ...
The Scan by 2 Minute Medicine® is a pop-culture medical newsletter and exclusive benefit for 2 Minute Medicine Plus subscribers. ...
1. Oral semaglutide adds a pill-based option for chronic obesity care without changing the core GLP-1 tradeoffs in efficacy and ...
The Scan by 2 Minute Medicine® is a pop-culture medical newsletter and exclusive benefit for 2 Minute Medicine Plus subscribers. ...
The Scan by 2 Minute Medicine® is a pop-culture medical newsletter and exclusive benefit for 2 Minute Medicine Plus subscribers. Leucovorin ...
1. Novo Nordisk expanded into self replicating RNA for obesity and T2D (type 2 diabetes), signaling modality diversification beyond peptides. ...
Novo’s srRNA push expands cardiometabolic pipeline On August 28, Novo Nordisk announced a collaboration with Replicate Bioscience to pursue self ...
FDA Approves First-Ever Treatment for Non-Cystic Fibrosis Bronchiectasis Late last week, the U.S. Food and Drug Administration approved Insmed’s Brinsupri ...
1. The majority of treatment-related adverse events were mild-to-moderate gastrointestinal events with no reported deaths. 2. Amycretin resulted in significant ...
1. Maximum walking distance at 52 weeks was significantly improved with semaglutide. 2. There were fewer treatment-related serious adverse events ...
